Seeking Alpha

Leerink Swann weighs in on Questcor Pharmaceuticals (QCOR +9.6%) after Medicaid's bump-up in...

Leerink Swann weighs in on Questcor Pharmaceuticals (QCOR +9.6%) after Medicaid's bump-up in reimbursement rates, upping its revenue projection on the company to $675M from $626M and its EPS estimates from $3.67 to $4.21.
Comments (1)
  • drdon
    , contributor
    Comments (198) | Send Message
     
    Today's action and market reaction bodes well for QCOR and all of us who stayed strong long throughout the recent bout with the shorts. There is and will continue to be a short squeeze as a background to a well positioned company with an impeccable corporate model.
    4 Sep 2012, 04:46 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|